Skip to content
  • Saturday, 15 August 2026
  • 1:32 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • FDA Approves Langlara, an Interchangeable Biosimilar for Diabetes Management, Expanding Patient Access and Treatment Options
Pharmaceutical R&D

FDA Approves Langlara, an Interchangeable Biosimilar for Diabetes Management, Expanding Patient Access and Treatment Options

Teuku Ryan May 6, 2026 0

Sunshine Lake Pharma, Lannett Company, and its wholly owned subsidiary Lanexa Biologics have achieved a significant milestone in diabetes care…

Read More
Pharmaceutical R&D

Teva Pharmaceutical Secures FDA Approval for Ponlimsi Biosimilar to Prolia, Advances Xolair Biosimilar Applications in US and EU

Teuku Ryan Apr 1, 2026 0

Teva Pharmaceutical has announced a significant milestone in its biosimilar portfolio with the U.S. Food and Drug Administration (FDA) granting…

Read More
‘Bionic skin’ kills bacteria and cools temperature to speed up infected wound healingLong-Term Chlorpyrifos Exposure Linked to 2.5-Fold Increase in Parkinson’s Disease Risk UCLA Researchers FindJ&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth StrategyHow ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ